全文获取类型
收费全文 | 4743篇 |
免费 | 338篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 91篇 |
妇产科学 | 53篇 |
基础医学 | 631篇 |
口腔科学 | 72篇 |
临床医学 | 588篇 |
内科学 | 899篇 |
皮肤病学 | 55篇 |
神经病学 | 655篇 |
特种医学 | 199篇 |
外科学 | 569篇 |
综合类 | 49篇 |
现状与发展 | 1篇 |
一般理论 | 8篇 |
预防医学 | 454篇 |
眼科学 | 133篇 |
药学 | 313篇 |
中国医学 | 3篇 |
肿瘤学 | 287篇 |
出版年
2023年 | 25篇 |
2022年 | 31篇 |
2021年 | 86篇 |
2020年 | 52篇 |
2019年 | 79篇 |
2018年 | 98篇 |
2017年 | 67篇 |
2016年 | 74篇 |
2015年 | 119篇 |
2014年 | 140篇 |
2013年 | 201篇 |
2012年 | 280篇 |
2011年 | 342篇 |
2010年 | 200篇 |
2009年 | 167篇 |
2008年 | 303篇 |
2007年 | 347篇 |
2006年 | 300篇 |
2005年 | 290篇 |
2004年 | 272篇 |
2003年 | 304篇 |
2002年 | 251篇 |
2001年 | 59篇 |
2000年 | 59篇 |
1999年 | 55篇 |
1998年 | 65篇 |
1997年 | 53篇 |
1996年 | 31篇 |
1995年 | 37篇 |
1994年 | 29篇 |
1993年 | 33篇 |
1992年 | 37篇 |
1991年 | 61篇 |
1990年 | 42篇 |
1989年 | 25篇 |
1988年 | 34篇 |
1987年 | 34篇 |
1986年 | 22篇 |
1985年 | 30篇 |
1984年 | 30篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 26篇 |
1980年 | 25篇 |
1979年 | 19篇 |
1978年 | 17篇 |
1977年 | 13篇 |
1975年 | 13篇 |
1974年 | 15篇 |
1972年 | 12篇 |
排序方式: 共有5097条查询结果,搜索用时 15 毫秒
101.
Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hague C Uberti MA Chen Z Bush CF Jones SV Ressler KJ Hall RA Minneman KP 《Proceedings of the National Academy of Sciences of the United States of America》2004,101(37):13672-13676
Olfactory receptors (ORs) comprise more than half of the large class I G protein-coupled receptor (GPCR) superfamily. Although cloned over a decade ago, little is known about their properties because wild-type ORs do not efficiently reach the cell surface following heterologous expression. Receptor-receptor interactions strongly influence surface trafficking of other GPCRs, and we examined whether a similar mechanism might be involved in OR surface expression. Olfactory neurons are known to express beta-adrenergic receptors (ARs), and we found that coexpression with beta(2)-ARs, but not any other AR subtypes, dramatically increased mouse 71 (M71) OR surface expression in human embryonic kidney 293 cells. A persistent physical interaction between M71 ORs and beta(2)-ARs was shown by coimmunoprecipitation and by cointernalization of the two receptors in response to their specific ligands. Also, coexpression of wild-type M71 ORs with beta(2)-ARs resulted in cAMP responses to the M71 ligand acetophenone. Finally, in situ hybridization studies showed extensive colocalization of M71 OR and beta(2)-AR expression in mouse olfactory epithelium. These data demonstrate the successful heterologous surface expression of a functional wild-type OR and reveal that persistent physical association with other GPCRs can control OR surface expression. 相似文献
102.
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Katharine H. Xing Amrit Kahlon Brian F. Skinnider Joseph M. Connors Randy D. Gascoyne Laurie H. Sehn Kerry J. Savage Graham W. Slack Tamara N. Shenkier Richard Klasa Alina S. Gerrie Diego Villa 《British journal of haematology》2015,169(4):520-527
Splenic marginal zone lymphoma (SMZL) accounts for less than 2% of all non‐Hodgkin lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from the British Columbia Cancer Agency Centre for Lymphoid Cancer and Lymphoma Pathology Databases. Patient characteristics were: median age 67 years (range 30–88), male 40%, stage IV 98%, splenomegaly 93%, bone marrow involvement 96%, peripheral blood involvement 87%. As initial treatment, 52 underwent splenectomy (10 with chemotherapy), 38 chemotherapy alone (21 chemoimmunotherapy containing rituximab, 1 rituximab alone), two antivirals for hepatitis C, and 15 were only observed. The 10‐year overall survival for first‐line splenectomy versus chemotherapy was 61% and 42%, respectively [Hazard Ratio (HR) 0·48, 95% confidence interval (CI) 0·26–0·88, P = 0·017]. The 10‐year failure‐free survival (FFS) after first‐line splenectomy vs chemotherapy was 39% and 14%, respectively (HR 0·48, 95% CI 0·28–0·80, P = 0·004). Among the 38 patients who received first‐line chemotherapy, FFS was similar between those receiving rituximab (n = 22) and those who did not (n = 16) (HR 0·64, 95% CI 0·31–1·34, P = 0·238). Fifteen patients transformed to aggressive lymphoma with median time to transformation of 3·5 years (range 6 months to 12 years) and the 10‐year transformation rate was 18%. In conclusion, splenectomy remains a reasonable treatment for patients with SMZL. 相似文献
103.
104.
Samantha L. Kendrick Lucas Redd Andrea Muranyi Leigh A. Henricksen Stacey Stanislaw Lynette M. Smith Anamarija M. Perry Kai Fu Dennis D. Weisenburger Andreas Rosenwald German Ott Randy D. Gascoyne Elaine S. Jaffe Elías Campo Jan Delabie Rita M. Braziel James R. Cook Raymond R. Tubbs Louis M. Staudt Wing Chung Chan Christian Steidl Thomas M. Grogan Lisa M. Rimsza 《Human pathology》2014
105.
Mireille Claustres Viktor Ko?ich Els Dequeker Brain Fowler Jayne Y Hehir-Kwa Konstantin Miller Cor Oosterwijk Borut Peterlin Conny van Ravenswaaij-Arts Uwe Zimmermann Orsetta Zuffardi Ros J Hastings David E Barton 《European journal of human genetics : EJHG》2014,22(2):160-170
Genetic test results can have considerable importance for patients, their parents and more remote family members. Clinical therapy and surveillance, reproductive decisions and genetic diagnostics in family members, including prenatal diagnosis, are based on these results. The genetic test report should therefore provide a clear, concise, accurate, fully interpretative and authoritative answer to the clinical question. The need for harmonizing reporting practice of genetic tests has been recognised by the External Quality Assessment (EQA), providers and laboratories. The ESHG Genetic Services Quality Committee has produced reporting guidelines for the genetic disciplines (biochemical, cytogenetic and molecular genetic). These guidelines give assistance on report content, including the interpretation of results. Selected examples of genetic test reports for all three disciplines are provided in an annexe.Diagnostic genetic testing is an extremely rapidly expanding area encompassing a broad range of laboratory investigations to analyse chromosomes (from classical karyotype to molecular cytogenetics), nucleic acids (DNA, RNA), proteins and metabolites used to detect heritable or somatic mutations, genotypes or phenotypes related to disease and health. Genetic testing requires particular consideration in that it is usually performed only once in a patient''s lifetime, and the results may have considerable importance for lifetime decisions not only for the individuals being tested but also for children and family. Interpreting and reporting variation in germline chromosomes, DNA sequences or their products is a heavy clinical responsibility for prediction of susceptibility to disease, patient diagnosis, prognosis, counselling, treatment or family planning. Providing a set of reporting frameworks that can be customised for different testing contexts but share some common principles could be beneficial to the practice of a number of laboratories, including non-OECD members and/or laboratories that do not participate in External Quality Assessments (EQA), and to laboratories with blurred boundaries between research and genetic testing services.Although several guidelines already exist for reporting the results of genetic testing,1,2,3 these focus on molecular genetic testing and do not cover the other two branches of laboratory genetics, namely biochemical genetics and cytogenetics. Based on recent surveys of EQA results presented by some European EQA providers and the request from genetic laboratories for comprehensive reporting guidelines, it was considered that a unifying attempt to harmonise the reporting practice of genetic tests in Europe and neighbouring countries would be welcome. 相似文献
106.
107.
Isik Unlu Ary Farajollahi Ilia Rochlin Taryn N. Crepeau Daniel Strickman Randy Gaugler 《Acta tropica》2014
Suppression of Aedes albopictus populations is a substantial challenge for mosquito control programs globally because juveniles of this species are found in numerous kinds of domestic artificial containers that are difficult to detect, access, and eliminate. We conducted a multi-year assessment of the effect of different interventions to control Ae. albopictus near the northernmost geographic boundary of the species in temperate North America and deployed an array of BG-Sentinel traps for adult surveillance. Here we present the results of a comparative examination of adult sex ratios in urban and suburban areas, shifts in sex ratios after control interventions, and a discussion of the critical drivers of population dynamics of Ae. albopictus in our area. We collected significantly more male mosquitoes in urban as compared to suburban areas in June through September, but not in May (p < 0.001). The higher number of male mosquitoes in urban areas could be attributed to a higher number of larval habitats within a closer proximity of the surveillance traps and the lower flight dispersal of males. Following application of adulticides in urban areas, Ae. albopictus male populations were reduced by 88% on average, which was higher than the 69% reduction in female populations. The higher reduction of male mosquitoes could be attributed to the smaller body mass of the males and their higher susceptibility to adulticides. The results of this study are directly relevant to the development of suitable control strategies that depend on manipulation of males, such as the sterile insect technique. The results could also be used to refine mosquito abatement by providing more accurate methods to determine the need and timing of vector control. 相似文献
108.
109.
110.
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma 总被引:1,自引:0,他引:1
Xie L Ushmorov A Leithäuser F Guan H Steidl C Färbinger J Pelzer C Vogel MJ Maier HJ Gascoyne RD Möller P Wirth T 《Blood》2012,119(15):3503-3511